Skip to main content
Gap Jumps On Q3 Beat, Higher FY25 Sales Outlook
Friday, November 21, 2025 - 12:13pm
Gap Sign On Building Exterior

Gap shares rose Friday after the company company beat third‑quarter expectations and lifted its full‑year sales outlook.

Read more
Earnings, News, Guidance, Movers
BlueBird 6 Launch Nears As AST SpaceMobile Races To Build Space Broadband Network
Friday, November 21, 2025 - 12:06pm
AST Spacemobile company logo on mobile device with stock chart in the background

AST SpaceMobile's BlueBird 6 satellite to launch on Dec 15 from India's space center. It's part of the company's cellular broadband network.

Read more
Equities, Large Cap, News, Top Stories, Movers
10 Industrials Stocks Moving In Friday's Intraday Session
Friday, November 21, 2025 - 12:05pm
movers image
Movers
12 Consumer Discretionary Stocks Moving In Friday's Intraday Session
Friday, November 21, 2025 - 12:05pm
movers image
Movers
12 Health Care Stocks Moving In Friday's Intraday Session
Friday, November 21, 2025 - 12:05pm
movers image
Movers
12 Information Technology Stocks Moving In Friday's Intraday Session
Friday, November 21, 2025 - 12:05pm
movers image
Movers
Bitcoin Meltdown Slams ETF Market: 5 Funds Hit Fresh Lows As Traders Hunt A Bottom
Friday, November 21, 2025 - 11:51am
Bitcoin symbol with the words ETF spelled out below it

A wave of crypto-linked ETFs plunged to fresh 52-week lows Friday morning, led lower by Bitcoin’s Read more

Cryptocurrency, Specialty ETFs, Top Stories, Movers, Trading Ideas, ETFs
Intuit Posts Strong Q3 On Higher AI Adoption To 'Reinvigorate' Growth
Friday, November 21, 2025 - 11:50am
Intuit

Shares of Intuit soared in early trading on Friday, after the company reported upbeat fiscal first-quarter earnings.

Read more
Analyst Color, Earnings, Earnings Beats, Reiteration, Analyst Ratings, Movers, Trading Ideas
Contineum Therapeutics' Multiple Sclerosis Trial Disappoints, But Analyst Sees Other Assets Driving Value
Friday, November 21, 2025 - 11:49am
Contineum Therapeutics, Inc company logo displayed on mobile phone

Contineum's Multiple Sclerosis drug missed key goals in a Phase 2 trial as RBC cut its target but highlighted stronger potential in the company's idiopathic pulmonary fibrosis program.

Read more
Analyst Color, Biotech, News, Health Care, Analyst Ratings, Movers, Trading Ideas, General